Fedratinib-d9
Fedratinib-d9 (TG-101348-d9) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research[1][2][3].
Product Specifications
Product Name Alternative
TG-101348-d9; SAR 302503-d9
UNSPSC
12352005
Target
Apoptosis; Isotope-Labeled Compounds; JAK
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=S(C1=CC=CC(NC2=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=NC=C2C)=C1)(NC(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=O
Molecular Formula
C27H27D9N6O3S
Molecular Weight
533.73
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Canine w-3 unsaturated fatty acids ELISA Kit
Canine w-3 unsaturated fatty acids ELISA Kit